Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pulmonx's interest expense for the
three
months ended in Mar. 2026 was $ -0.98 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.35 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pulmonx's Operating Income for the
three
months ended in Mar. 2026 was $ -12.96 Mil. Pulmonx's Interest Expense for the
three
months ended in Mar. 2026 was $ -0.98 Mil.
Pulmonx did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Pulmonx (NAS:LUNG) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Pulmonx's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
Pulmonx did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Pulmonx Interest Expense Historical Data
* Premium members only.
The historical data trend for Pulmonx's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx (LUNG) has a Interest Expense of $-3.35 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pulmonx and its competitors.
Is Pulmonx's Interest Expense too high?
Pulmonx's current Interest Expense is $-3.35 Mil. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Interest Expense compare to MDAI and QTI?
Pulmonx's Interest Expense of $-3.35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pulmonx and its competitors. Pulmonx's current Interest Expense is $-3.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.53 — trading 78.5% below its estimated fair value. The current Interest Expense is $-3.35 Mil. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pulmonx (LUNG), the current Interest Expense is $-3.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (LUNG) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of $1.53 is trading 78.5% below its estimated GF Value™ of $7.13.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for LUNG:
Interest Expense: $-3.35 Mil
GF Value™: $7.13 vs. price of $1.53 (78.5% below fair value)
No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score
Get the complete analysis for LUNG
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUNG has been successfully added to your 
